On Tuesday, Shares of IMS Health Holdings Inc (NYSE:IMS), lost -0.35% to $31.40.
The number of mobile health applications available to consumers now surpasses 165,000, as developers incorporate innovative data collection features linked to sensors and wearables, according to a new report released recently by the IMS Institute for Healthcare Informatics. While most available apps focus on overall wellness, healthcare systems and professionals are expressing greater interest and excitement in broader app use as barriers to mainstream adoption of mHealth are removed—especially in the area of chronic disease administration.
The IMS Institute study found that one in ten apps now has the capability to connect to a device or sensor, providing biofeedback and physiological function data from the patient and greatly extending the accuracy and convenience of data collection. Nearly a quarter of consumer apps are now focused on disease and treatment administration, while two-thirds target fitness and wellness. The number and variety of mHealth apps present an overwhelming set of options for consumers, resulting in 40 percent of apps having fewer than 5,000 downloads.
The study, Patient Adoption of mHealth: Use, Evidence and Remaining Barriers to Mainstream Acceptance, extends the IMS Institute’s examination of consumer-focused mobile apps in the health system conducted in 2013. Researchers drew on IMS Health’s proprietary AppScript Score database and analysis of 26,864 apps available in the U.S. Apple iTunes and Android app stores—a representative sample of the most widely used mHealth apps by consumers. As part of the study, the IMS Institute also conducted structured interviews with health- and technology-focused thought leaders and executives on the role and status of healthcare apps.
IMS Health Holdings, Inc. (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Company’s data set contains over 10 petabytes of data and over 500 million patient records.
Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI), declined -4.82% to $9.48, during its last trading session.
Infinity Pharmaceuticals, declared that it will host a live webcast in conjunction with its 2015 Research & Development (R&D) Day for analysts and institutional investors on Tuesday, October 6, 2015, in New York City. At the meeting, Infinity plans to review the clinical development program for duvelisib and discuss the company’s newest development candidate, IPI-549. Additionally, presentations will be given by the following expert physicians:
- Jennifer R. Brown, M.D., Ph.D., director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School
- Steven M. Horwitz, M.D., associate attending for the Lymphoma Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center
- David A. Tuveson, M.D., Ph.D., Roy J. Zuckerberg professor of cancer research, director Cancer Therapeutics Initiative and deputy director of Cancer Center at Cold Spring Harbor Laboratory, director of research, the Lustgarten Foundation
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology.
At the end of Tuesday’s trade, Shares of Owens Corning (NYSE:OC), lost -3.68% to $44.79.
Owens Corning, has earned placement in the Dow Jones Sustainability World Index (DJSI World) in recognition of its sustainability initiatives.
For the third straight year, Owens Corning was named the Industry Leader for the DJSI World Building Products group.
Composed of global sustainability leaders, the DJSI World is an elite listing of the world’s largest companies based on long-term economic, environmental and social criteria.
Owens Corning is a holding company. The Company is engaged in composite and building materials systems. The Company’s products range from glass fiber used to reinforce composite materials for transportation, electronics, marine, infrastructure, wind energy and other markets to insulation and roofing for residential, commercial and industrial applications. The Company operates under three segments: Composites, Insulation and Roofing.
Finally, Callon Petroleum Company (NYSE:CPE), ended its last trade with -2.85% loss, and closed at $8.19.
Callon Petroleum Company, declared that senior administration plans to take part in the forthcoming investor event:
Johnson Rice Energy Conference
The Company will present at the Energy Conference hosted by Johnson Rice & Company LLC in New Orleans, LA on Tuesday, September 29, 2015 at 11:00 am Central Time.
Callon Petroleum Company is an independent oil and natural gas company. The Company is engaged in the exploration, development, acquisition and production of oil and natural gas properties. The Company is focused on unconventional, onshore, oil and natural gas reserves in the Permian Basin in West Texas and the Midland Basin.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
